Annovis Bio, Inc. (NYSE:ANVS) Given Average Rating of “Buy” by Analysts

Shares of Annovis Bio, Inc. (NYSE:ANVS) have earned a consensus rating of “Buy” from the six ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $31.40.

ANVS has been the topic of several recent research reports. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Annovis Bio in a research report on Monday, November 11th. Maxim Group raised Annovis Bio from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a report on Friday, October 25th.

Institutional Investors Weigh In On Annovis Bio

A number of institutional investors and hedge funds have recently bought and sold shares of ANVS. Greenwich Wealth Management LLC boosted its stake in shares of Annovis Bio by 19.9% in the second quarter. Greenwich Wealth Management LLC now owns 15,075 shares of the company’s stock worth $87,000 after acquiring an additional 2,500 shares during the period. XTX Topco Ltd bought a new position in Annovis Bio in the 2nd quarter worth approximately $115,000. Quest Partners LLC purchased a new stake in Annovis Bio during the 3rd quarter valued at approximately $371,000. State Street Corp raised its position in shares of Annovis Bio by 23.7% during the third quarter. State Street Corp now owns 36,035 shares of the company’s stock valued at $290,000 after buying an additional 6,900 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Annovis Bio by 30.0% in the third quarter. Geode Capital Management LLC now owns 99,114 shares of the company’s stock worth $799,000 after buying an additional 22,881 shares in the last quarter. 15.83% of the stock is owned by institutional investors.

Annovis Bio Stock Performance

Annovis Bio stock opened at $4.90 on Friday. Annovis Bio has a one year low of $4.21 and a one year high of $20.00. The stock has a fifty day moving average of $6.10 and a 200 day moving average of $8.02. The stock has a market cap of $67.61 million, a PE ratio of -1.10 and a beta of 1.64.

Annovis Bio (NYSE:ANVS) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.33). As a group, sell-side analysts predict that Annovis Bio will post -2.19 EPS for the current fiscal year.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.